Considering the preventive effect of the homozygous CCR5-Δ32 genotype in HIV infection, inhibiting the successful binding of HIV to CD4+ T cells [52], the presence of heterozygous CCR5-Δ32 in an HIV patient is therefore expected to reduce the rate of viral replication, thereby enhancing positive disease outcomes similar to the clinical experience of ECs and LTNPs [8]. This evidence concerns the gene CD4 and HIV infectious disease.